• Posted: November 19, 2015 Efficacy and safety of salvage therapy using Carfilzomib for relapsed or...

    Muchtar E, Gatt ME, Rouvio O, Ganzel C, Chubar E, Suriu C, Tadmor T, Shevetz O, Lavi N, Shochat T, Cohen YC, Avivi I, Raanani P, Magen H. Br J Haematol. 2015...

    READ MORE
  • Posted: November 16, 2015 Statement from Walter M. Capone, President and CEO of the Multiple Myeloma...

    “The approval of daratumumab brings another promising advance in the therapeutic landscape for patients with significant unmet needs. The MMRF is proud to...

    READ MORE
  • Posted: November 4, 2015 Patients as Drivers: A Prescription for the Future

    It's a different world than when I was diagnosed in 1996 with the incurable cancer multiple myeloma. Today, thanks to advances in sequencing technologies, we...

    READ MORE
  • Posted: October 22, 2015 T cell exhaustion/senescence characterizes multiple myeloma relapse after...

    Chung DJ, Pronschinske KB, Shyer JA, Sharma S, Leung S, Curran SA, Lesokhin AM, Devlin SM, Giralt S, Young JW. Cancer Immunol Res. 2015 Oct 13. pii:...

    READ MORE
  • Posted: October 22, 2015 PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests...

    Sponaas AM, Moharrami NN, Feyzi E, Standal T, Holth Rustad E, Waage A, Sundan A. PLoS One. 2015 Oct 7;10(10):e0139867. doi: 10.1371/journal.pone.0139867....

    READ MORE
  • Posted: October 22, 2015 HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to...

    Canella A, Nieves HC, Sborov DW, Cascione L, Radomska HS, Smith E, Stiff A, Consiglio J, Caserta E, Rizzotto L, Zanesi N, Stefano V, Kaur B, Mo X, Byrd JC,...

    READ MORE
  • Posted: October 22, 2015 Dexamethasone-induced cell death is restricted to specific molecular subgroups...

    Kervoëlen C, Ménoret E, Gomez-Bougie P, Bataille R, Godon C, Marionneau-Lambot S, Moreau P, Pellat-Deceunynck C, Amiot M. Oncotarget. 2015 Sep...

    READ MORE
  • Posted: October 22, 2015 Cytogenetics and long-term survival of patients with refractory or relapsed and...

    Dimopoulos MA, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J,...

    READ MORE
  • Posted: October 22, 2015 The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib...

    Kraus M, Bader J, Geurink PP, Weyburne ES, Mirabella AC, Silzle T, Shabaneh TB, van der Linden WA, de Bruin G, Haile SR, van Rooden E, Appenzeller C, Li N,...

    READ MORE
  • Posted: October 22, 2015 Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With...

    Squifflet P, Michiels S, Siegel D, Vij R, Jagannath S, Saad ED, Rajangam K, Ro SK, Buyse M. Clin Lymphoma Myeloma Leuk. 2015 Sep 25. pii:...

    READ MORE

Page 13/15